{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:48:39Z","timestamp":1788580119161,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.08.086","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T20:25:35Z","timestamp":1694291135000},"page":"6146-6149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals"],"prefix":"10.1016","volume":"41","author":[{"given":"James M.","family":"McCarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Mendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Ledgerwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Royalty","family":"Tredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Warfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.08.086_b0005","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/517537","article-title":"Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients","volume":"44","author":"Borgherini","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.086_b0010","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1099\/vir.0.82858-0","article-title":"Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus","volume":"88","author":"Powers","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2023.08.086_b0015","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya virus and the global spread of a mosquito-borne disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.08.086_b0020","unstructured":"https:\/\/www.paho.org\/hq\/dmdocuments\/2015\/2015-may-15-cha-CHIKV-cumulative-cases.pdf. Accessed 14 April, 2023."},{"key":"10.1016\/j.vaccine.2023.08.086_b0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(14)60185-9","article-title":"Chikungunya in the Americas","volume":"383","author":"Leparc-Goffart","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.08.086_b0030","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/518701","article-title":"Chikungunya fever in travelers: clinical presentation and course","volume":"45","author":"Taubitz","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.086_b0035","doi-asserted-by":"crossref","first-page":"e0003764","DOI":"10.1371\/journal.pntd.0003764","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.08.086_b0040","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.08.086_b0045","doi-asserted-by":"crossref","unstructured":"Noranate N, Takeda N, Chetanachan P, Sittisaman P, A-Nuegoonpipat A, Anantapreecha S. Characterization of chikungunya virus-like particles. PloS One. 2014;9(9):e108169. doi:10.1371\/journal.pone 0108169.","DOI":"10.1371\/journal.pone.0108169"},{"key":"10.1016\/j.vaccine.2023.08.086_b0050","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.08.086_b0055","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","article-title":"A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all chikungunya virus genotypes","volume":"214","author":"Goo","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.086_b0060","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vaccine.2023.08.086_b0065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide\u2013adjuvanted chikungunya virus\u2013like particle vaccine: results of a randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.086_b0070","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.086_b0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herve","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2023.08.086_b0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2310\/7060.2004.19002","article-title":"Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine","volume":"11","author":"Beck","year":"2004","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.08.086_b0085","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1016\/j.vaccine.2011.08.076","article-title":"Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines","volume":"29","author":"Andrews","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.086_b0090","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.vaccine.2012.04.052","article-title":"Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults","volume":"30","author":"Grabenstein","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.086_b0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/599824","article-title":"Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55\u201370 years of age","volume":"49","author":"Miernyk","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.086_b0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1045-1870(03)00033-5","article-title":"Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines","volume":"14","author":"Rennels","year":"2003","journal-title":"Semin Pediatr Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.08.086_b0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0891-5520(05)70272-5","article-title":"Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults","volume":"15","author":"Gardner","year":"2001","journal-title":"Infect Dis Clin North Am"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:02Z","timestamp":1759404602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23010526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":21,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X23010526"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}